Pulls the AlienVault OTX reports ("pulses") that name a selected indicator, and stages the substantial ones as campaigns — with their ATT&CK techniques, malware families and named adversary. Every ...

Microsoft Build is officially over, but there’s still a lot to unpack. If there’s one single through line from Build, it’s that Microsoft is all in on AI — for Windows, for its Surface Laptops and ...

Microsoft today unveiled Majorana 2, its newest topological quantum chip featuring a next-generation materials stack and qubits that are 1,000 times more reliable than their predecessors. With this ...

Microsoft stock has performed well over the past several years. As of early December 2025, Microsoft had produced a more than 17% total return in 2025, outpacing the S&P 500’s over 16% return. The ...

ESET researchers have discovered a previously undocumented China-aligned APT group that we named GopherWhisper. The group wields a wide array of tools mostly written in Go, using injectors and loaders ...

Ocular Therapeutix targets retinal diseases, focusing on wet age-related macular degeneration (AMD) with its lead candidate, AXPAXLI (OTX-TKI). Current wet AMD treatment is dominated by anti-VEGF ...

Ocular Therapeutix (OCUL) is a Strong Buy, driven by the pivotal SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline results expected Q1 2026. AXPAXLI™ leverages proven science and a de-risked ...

In Atlanta, Microsoft has flipped the switch on a new class of datacenter – one that doesn’t stand alone but joins a dedicated network of sites functioning as an AI superfactory to accelerate AI ...

Orbital Therapeutics is currently running IND-enabling studies for its lead candidate. (iStock / Getty Images Plus) The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing ...

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases Transaction further ...